List of Excipients in Branded Drug EXJADE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Novartis Pharmaceuticals Corporation	EXJADE	deferasirox	0078-0468	CELLULOSE, MICROCRYSTALLINE
Novartis Pharmaceuticals Corporation	EXJADE	deferasirox	0078-0468	CROSPOVIDONE
Novartis Pharmaceuticals Corporation	EXJADE	deferasirox	0078-0468	LACTOSE MONOHYDRATE
Novartis Pharmaceuticals Corporation	EXJADE	deferasirox	0078-0468	MAGNESIUM STEARATE

Last updated: August 9, 2026

Exjade (deferasirox) created commercial opportunities in excipient substitution, taste masking, pediatric delivery, solid-state control, and lower-cost generic manufacturing. Its original dispersible-tablet platform used a conventional excipient system, but the product’s administration burden and gastrointestinal tolerability supported migration to Jadenu film-coated tablets and Jadenu Sprinkle granules. The principal opportunity is now generic and differentiated reformulation development rather than restoration of broad molecule-level exclusivity.

Exjade Excipient Strategy and Commercial Opportunities for Deferasirox

What is Exjade and how does its formulation work?

Exjade is Novartis’ original oral deferasirox product for chronic iron overload caused by transfusions and non-transfusion-dependent thalassemia. The product is an orally administered iron chelator supplied as tablets for suspension.

Exjade uses a dispersible-tablet formulation. Patients disperse the tablet in water or another approved liquid before administration. This approach supports delivery of a poorly water-soluble active pharmaceutical ingredient but creates practical disadvantages:

• Preparation is required before every dose.
• The suspension has an undesirable taste.
• Administration is less convenient than swallowing a conventional tablet.
• Dosing errors can occur if the container is not rinsed and the full dose is not consumed.
• Gastrointestinal adverse effects can reduce adherence.

Novartis later introduced Jadenu film-coated tablets and Jadenu Sprinkle granules. These products use the same active ingredient, deferasirox, but address administration and patient-preference limitations associated with Exjade.[1][2]

What active ingredient and dosage forms are used?

Product	Active ingredient	Main dosage form	Commercial role
Exjade	Deferasirox	Tablets for oral suspension	Original branded product
Jadenu	Deferasirox	Film-coated tablets	Lower-volume, swallowable formulation
Jadenu Sprinkle	Deferasirox	Oral granules	Administration with soft food
Generic deferasirox	Deferasirox	Tablets for suspension, tablets, or other approved forms	Post-exclusivity competition

The transition from Exjade to Jadenu changed the excipient strategy from a dispersible suspension platform to solid oral dosage forms with improved convenience and reduced administration volume.

What excipients are used in Exjade tablets?

Exjade tablets contain excipients selected for rapid dispersion, tablet integrity, wetting, powder flow, and manufacturability. The FDA prescribing information identifies the following inactive ingredients for Exjade tablets for oral suspension:

• Lactose monohydrate
• Microcrystalline cellulose
• Crospovidone
• Povidone
• Sodium lauryl sulfate
• Colloidal silicon dioxide
• Magnesium stearate

The excipient system has distinct functional roles.

Excipient	Primary formulation function
Lactose monohydrate	Diluent and tablet bulk
Microcrystalline cellulose	Binder, compressibility aid, and structural filler
Crospovidone	Superdisintegrant
Povidone	Binder and granulation aid
Sodium lauryl sulfate	Wetting agent and surfactant
Colloidal silicon dioxide	Glidant and flow aid
Magnesium stearate	Lubricant

Crospovidone and sodium lauryl sulfate are particularly important in a dispersible tablet. Crospovidone promotes rapid breakup in water, while sodium lauryl sulfate improves wetting of hydrophobic deferasirox particles. The formulation therefore relies on coordinated disintegration and wetting rather than simple tablet dissolution.

What excipient risks exist in the Exjade formulation?

The principal risks are formulation performance and patient acceptability rather than excipient patentability.

Lactose can create a labeling issue for patients with lactose intolerance, although the quantity in a tablet may be clinically acceptable for many patients. Sodium lauryl sulfate can contribute to irritation or taste concerns. Magnesium stearate can impair wetting if over-lubrication occurs. Crospovidone particle size and concentration can affect dispersion time and suspension uniformity.

For generic manufacturers, the key development controls are:

1. Deferasirox particle-size distribution.
2. Solid-state form and crystallinity.
3. Blend uniformity at low and high strengths.
4. Dispersion time.
5. Suspension homogeneity.
6. Dose recovery after container rinsing.
7. Stability under humidity stress.
8. Comparative dissolution or drug-release performance.
9. Taste and mouthfeel.
10. Excipient compatibility with the active ingredient.

How does Jadenu compare with Exjade from an excipient perspective?

Jadenu reduces the administration burden through a more compact, swallowable dosage form. Its label identifies a core system that includes microcrystalline cellulose, crospovidone, povidone, sodium lauryl sulfate, colloidal silicon dioxide, and magnesium stearate. The film coating contains standard coating materials, including hypromellose, titanium dioxide, talc, and colorants depending on strength.[2]

The key difference is the absence of lactose from the core excipient list reported for Jadenu film-coated tablets. The dosage form also removes the need for pre-dispersion in water.

Attribute	Exjade	Jadenu
Administration	Disperse in liquid	Swallow tablet
Core strategy	Rapid disintegration and wetting	Compact tablet with film coating
Lactose	Listed in inactive ingredients	Not listed in the core formulation described in the label
Patient preparation	Required	Not required
Taste exposure	Higher because of suspension	Lower because of coating
Manufacturing challenge	Dispersion and suspension performance	Compression, coating, dissolution, and dose proportionality
Reformulation opportunity	Taste masking and dispersion improvement	Smaller tablet, sprinkle delivery, modified release, and pediatric optimization

Jadenu’s excipient strategy is commercially important because it demonstrates that the highest-value product improvement was not a new active ingredient. It was a delivery-system change supported by tablet engineering and patient-use advantages.

What formulation patents protect Exjade and deferasirox products?

Deferasirox has had protection from compound, pharmaceutical-composition, and product-specific patent families. The original active-ingredient and composition protection expired in the United States before the current generic market became established. Secondary protection has included formulation and product claims associated with solid oral dosage forms, dispersible tablets, and improved administration.

The commercial significance of these patents is now narrower:

• Broad deferasirox composition claims no longer provide a durable barrier to generic entry.
• Formulation claims may still affect specific branded presentations or manufacturing approaches.
• A generic applicant can often design around formulation claims by changing excipient grades, concentrations, coating systems, or processing steps.
• FDA approval depends on the applicable reference product and ANDA certification framework, not on use of identical excipients.

What is the Orange Book status of Exjade?

Exjade and Jadenu were approved under FDA new drug applications. The Orange Book records patent and exclusivity information for listed products, while generic deferasirox products enter through abbreviated new drug applications where the reference-product and patent-certification requirements apply.[3]

The relevant commercial point is that deferasirox has moved from a branded-exclusivity market into a generic market. An Orange Book listing does not automatically prevent approval. The practical effect depends on:

• The patent’s expiration date.
• Whether the patent is listed against the relevant strength or dosage form.
• The applicant’s Paragraph I, II, III, or IV certification.
• Whether the listed patent is enforceable.
• Whether litigation triggers a statutory stay.
• Whether the generic copies Exjade, Jadenu, or another reference presentation.

When did Exjade lose exclusivity and when did generic entry begin?

Exjade’s principal molecule-level protection expired before broad generic competition developed. Novartis extended the franchise through Jadenu, a reformulated version approved in 2015, and Jadenu Sprinkle, approved later for patients who could not easily swallow tablets.[2]

Generic deferasirox approvals began to materially change the market after the expiration of key protections and the resolution or exhaustion of relevant regulatory barriers. Generic applicants have pursued dosage forms corresponding to deferasirox tablets for oral suspension and film-coated tablets.

The market timeline is:

Period	Event	Commercial effect
2005	FDA approval of Exjade	Establishes the branded deferasirox market
2015	FDA approval of Jadenu	Introduces a swallowable tablet and extends franchise life
2019	FDA approval of Jadenu Sprinkle	Adds a soft-food administration option
2020 onward	Generic deferasirox approvals and market expansion	Increases price pressure and reduces branded share
Current market	Multiple deferasirox dosage-form strategies	Shifts value toward supply reliability, formulation differentiation, and contracting

The exact launch timing varies by product, dosage form, applicant, litigation resolution, and commercial decision. FDA’s Drugs@FDA and Orange Book databases are the controlling sources for approval and listing status.[3][4]

Which companies are challenging Exjade and Jadenu?

The generic competitive field includes companies that have sought FDA approval for deferasirox products under the ANDA pathway. The relevant competitive groups are:

• Large generic manufacturers with established hematology portfolios.
• Specialty generic companies targeting low-volume orphan and rare-disease products.
• Contract manufacturers supplying deferasirox tablets.
• Regional companies pursuing markets outside the United States.
• Branded manufacturers using authorized-generic or secondary-label strategies.

Competition is likely to focus on product availability and contracting rather than large promotional campaigns. Deferasirox is used in a specialized patient population, and treatment decisions can be influenced by hematology centers, hospital systems, payer formularies, and patient-support programs.

What Paragraph IV risks exist for deferasirox?

A Paragraph IV certification alleges that a listed patent is invalid, unenforceable, or not infringed. For deferasirox, Paragraph IV risk has been most relevant to secondary patents covering particular dosage forms or formulations rather than the basic active ingredient.

Potential litigation issues include:

• Whether a generic tablet falls within a formulation claim.
• Whether a process claim covers the generic manufacturing method.
• Whether the generic uses the same polymorph or particle-size distribution.
• Whether a label induces infringement of a patented method of use.
• Whether the listed patent is properly submitted to the Orange Book.
• Whether a product-specific patent covers Jadenu rather than Exjade.

A Paragraph IV filing can trigger patent litigation and, in some circumstances, a 30-month stay of FDA approval. The commercial impact depends on the asserted patent, the strength of the infringement theory, and the applicant’s ability to launch at risk.

What excipient opportunities exist for generic deferasirox?

The strongest opportunities are incremental. They do not require discovering a new active ingredient.

1. Lactose-free dispersible tablets

A lactose-free Exjade-equivalent formulation could target patients with lactose sensitivity and simplify excipient labeling. Direct substitution requires control of:

• Tablet hardness.
• Dispersion time.
• Suspension uniformity.
• Mouthfeel.
• Dose recovery.
• Stability.

Mannitol, dibasic calcium phosphate, or alternative grades of microcrystalline cellulose could replace lactose, but each changes compressibility, density, wetting, and taste.

2. Improved taste masking

Deferasirox has an unpleasant taste that is more exposed in a dispersed suspension. Commercial approaches include:

• Polymer coating of active particles.
• Ion-exchange or lipid-based taste-masking systems.
• Flavor systems compatible with pediatric use.
• Effervescent or rapidly dispersible formats.
• Reduced-contact granules.
• pH-controlled microenvironments.

Taste masking must not delay dispersion or reduce bioavailability. Excessive coating can create dissolution failures, while surfactants can produce foaming and poor mouthfeel.

3. Pediatric granules and sprinkle products

Jadenu Sprinkle shows the value of a formulation that can be administered with soft food. Generic developers can pursue:

• Smaller granule size.
• Reduced grittiness.
• Neutral flavor.
• Dose flexibility.
• Unit-dose sachets.
• Better compatibility with applesauce, yogurt, or other approved vehicles.

Pediatric products have a higher excipient burden because sweeteners, flavors, colors, and preservatives must be justified for chronic use.

4. Lower-dose and flexible-dose presentations

Deferasirox dosing is weight-based and may require titration. Commercial opportunity exists in strengths that reduce tablet splitting, minimize daily tablet count, and support pediatric dosing. Dose flexibility can improve adherence without creating a new mechanism of action.

5. Manufacturing-cost reduction

The original excipients are widely available and generally low cost. The largest savings are more likely to come from process optimization:

• Direct compression where feasible.
• Continuous blending.
• Controlled lubricant addition.
• High-speed coating.
• Reduced batch failure from poor dispersion.
• Robust moisture-barrier packaging.
• Use of qualified regional excipient suppliers.

Excipient changes that reduce cost but increase dissolution variability are unlikely to produce durable value.

How strong is the deferasirox formulation patent estate?

The estate is weaker against ordinary generic entry than it was during the branded period because the core active-ingredient protection has expired and common excipients are difficult to monopolize broadly.

Patent strength is higher where claims cover:

• A defined solid-state form.
• A narrow particle-size distribution.
• A specific dissolution profile.
• A particular granule architecture.
• A proprietary coating system.
• A combination of excipient ratios and processing conditions.
• A manufacturing process that is difficult to reproduce independently.

Patent strength is lower where claims depend on routine excipient substitutions or ordinary tablet-processing steps. Generic companies can often design around such claims with alternative diluents, binders, disintegrants, surfactants, or coating polymers.

What regulatory barriers affect excipient-based reformulation?

An excipient change can be straightforward when the product remains pharmaceutically equivalent and bioequivalent to the reference product. The regulatory burden rises when the change affects:

• Dosage form.
• Route or method of administration.
• Release profile.
• Food effect.
• Bioavailability.
• Pediatric exposure.
• Labeling of allergens or excipient sensitivities.
• Device or packaging performance.

An ANDA applicant must generally demonstrate pharmaceutical equivalence and bioequivalence. A product with a substantially different delivery system may require a 505(b)(2) application rather than a conventional ANDA.[5]

For a new sprinkle product, taste-masked product, or modified-release product, the most commercially defensible pathway may depend on whether the product can reference an approved deferasirox product while relying on new clinical, pharmacokinetic, or human-factors data.

What commercial opportunities remain after generic entry?

The most attractive opportunities are targeted rather than broad replacement of Exjade.

Opportunity	Commercial rationale	Main risk
Low-cost generic tablets	Large addressable treated population and established clinical use	Price erosion
Lactose-free suspension	Differentiated excipient profile	Need to preserve performance
Pediatric granules	Better administration for children	Taste and pediatric regulatory requirements
Unit-dose sachets	Improved adherence and portability	Packaging cost
Taste-masked product	Reduces treatment refusal	Bioavailability and dissolution risk
Hospital supply contracts	Predictable procurement demand	Low margins and tender pressure
Emerging-market products	Access and lower-cost manufacturing	Local registration and pricing controls
Authorized generic	Brand-controlled transition strategy	Limited differentiation
Excipient and CDMO supply	Recurring manufacturing revenue	Qualification and supply-chain concentration

Revenue exposure is concentrated in the branded franchise, generic price competition, and treatment persistence. Deferasirox is a chronic therapy, so a formulation that improves adherence can generate value even without increasing the treated population.

What manufacturing and geographic barriers affect deferasirox?

Deferasirox does not require biologic cold-chain manufacturing. The principal manufacturing barriers are solid-state control, powder handling, blend uniformity, dispersion performance, and moisture protection.

Geographic opportunities are strongest where transfusion-dependent thalassemia and sickle-cell disease create persistent iron-overload treatment demand. Relevant markets include the United States, Europe, the Middle East, South Asia, Southeast Asia, and parts of Africa.

Regional commercialization requires attention to:

• Country-specific reference-product rules.
• Local bioequivalence requirements.
• Approved excipient lists.
• Lactose and allergen labeling.
• Pediatric-use requirements.
• Local stability zones.
• Procurement and tender structures.
• Pharmacovigilance obligations.
• Availability of hematology specialists.

What is the litigation and settlement outlook for deferasirox?

The principal patent-litigation risk has shifted from molecule-level exclusion to product-specific disputes. Potential cases may involve an ANDA applicant’s Paragraph IV certification against listed formulation patents, process patents, or method-of-use claims.

Settlement agreements can affect launch timing through:

• Licensed entry dates.
• Authorized-generic commitments.
• Supply arrangements.
• Non-exclusive formulation licenses.
• Restrictions on dosage forms.
• Geographic carve-outs.

Publicly available FDA records, court dockets, patent assignments, and company filings should be reviewed together because an Orange Book listing alone does not establish the commercial launch date or the practical enforceability of a patent.[3][6]

Key Takeaways

• Exjade uses a dispersible deferasirox tablet built around lactose, microcrystalline cellulose, crospovidone, povidone, sodium lauryl sulfate, colloidal silicon dioxide, and magnesium stearate.
• The central excipient functions are wetting, rapid disintegration, binding, lubrication, and powder-flow control.
• Jadenu shifted the franchise to a swallowable film-coated tablet, while Jadenu Sprinkle added soft-food administration.
• Broad deferasirox exclusivity has expired, making generic entry and formulation differentiation the primary commercial issues.
• The strongest opportunities are taste masking, lactose-free suspension, pediatric granules, unit-dose packaging, flexible dosing, and cost-efficient manufacturing.
• Formulation patents are more vulnerable to design-around strategies than compound patents.
• Regulatory strategy determines whether a reformulation can proceed through an ANDA or requires a 505(b)(2) application.
• Commercial value depends on treatment adherence, hematology-channel access, supply reliability, and payer contracting.

FAQs About Exjade Excipients and Commercial Strategy

Can a generic Exjade product use different excipients?

Yes. A generic manufacturer may use different excipients if the product meets applicable pharmaceutical-equivalence, bioequivalence, quality, labeling, and safety requirements.

Is lactose essential to Exjade tablet performance?

No. Lactose is a diluent in the labeled Exjade formulation, but replacement is possible if the alternative excipient system preserves compression, dispersion, stability, and dose delivery.

Which Exjade excipient is most important for dispersion?

Crospovidone supports tablet breakup, while sodium lauryl sulfate improves wetting of deferasirox. Their interaction with particle size and lubrication level is more important than either excipient alone.

Can a company patent a new deferasirox excipient combination?

Potentially, but a patent would need sufficient novelty and non-obviousness. Routine substitution of one common diluent or disintegrant for another is vulnerable to validity challenges.

Is Jadenu a new drug or a reformulation of Exjade?

Jadenu contains the same active ingredient, deferasirox, but uses a different oral dosage form and administration approach. Its clinical and regulatory positioning reflects a reformulated product strategy.

Sources

1. U.S. Food and Drug Administration. (2023). Exjade (deferasirox) prescribing information.
2. U.S. Food and Drug Administration. (2023). Jadenu and Jadenu Sprinkle (deferasirox) prescribing information.
3. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2025). Drugs@FDA: FDA-approved drugs database.
5. U.S. Food and Drug Administration. (2019). Applications covered by section 505(b)(2).
6. Novartis AG. (2019). Annual report 2018.